Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics
Neuroblastoma serves as a paradigm for applying tumor genomic data for determining patient prognosis and thus for treatment allocation. MYCN status, i.e. amplified vs. non-amplified, was one of the very first biomarkers in oncology to discriminate aggressive from less aggressive or even favorable cl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00202/full |
| _version_ | 1818363479871979520 |
|---|---|
| author | Inge M. Ambros Clemens eBrunner Reza eAbbasi Christian eFrech Peter F. Ambros Peter F. Ambros |
| author_facet | Inge M. Ambros Clemens eBrunner Reza eAbbasi Christian eFrech Peter F. Ambros Peter F. Ambros |
| author_sort | Inge M. Ambros |
| collection | DOAJ |
| description | Neuroblastoma serves as a paradigm for applying tumor genomic data for determining patient prognosis and thus for treatment allocation. MYCN status, i.e. amplified vs. non-amplified, was one of the very first biomarkers in oncology to discriminate aggressive from less aggressive or even favorable clinical courses of neuroblastoma. However, MYCN amplification is by far not the only genetic change associated with unfavorable clinical courses: so called segmental chromosomal aberrations, i.e. gains or losses of chromosomal fragments, can also indicate tumor aggressiveness. The clinical use of these genomic aberrations has, however, been hampered for many years by methodical and interpretational problems. Only after reaching worldwide consensus on markers, methodology, and data interpretation, information on SCAs has recently been implemented in clinical studies. Now, a number of collaborative studies within COG, GPOH and SIOPEN use genomic information to stratify therapy for patients with localized and metastatic disease. Recently, new types of DNA based aberrations influencing the clinical behavior of neuroblastomas have been described. Deletions or mutations of genes like ATRX and a phenomenon referred to as chromothripsis are all assumed to correlate with an unfavorable clinical behavior. However, these genomic aberrations need to be scrutinized in larger studies applying the most appropriate techniques. Single nucleotide polymorphism (SNP) arrays have proven successful in deciphering genomic aberrations of cancer cells; these techniques, however, are usually not applied in the daily routine. Here, we present an ultra-high density (UHD) SNParray technique which is, because of its high specificity and sensitivity and the combined copy number and allele information, highly appropriate for the genomic diagnosis of neuroblastoma and other malignancies. |
| first_indexed | 2024-12-13T21:49:08Z |
| format | Article |
| id | doaj.art-263797fb779841b8aaa99bc4c16c9197 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T21:49:08Z |
| publishDate | 2014-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-263797fb779841b8aaa99bc4c16c91972022-12-21T23:30:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-08-01410.3389/fonc.2014.0020286201Ultra-high Density SNParray in Neuroblastoma Molecular DiagnosticsInge M. Ambros0Clemens eBrunner1Reza eAbbasi2Christian eFrech3Peter F. Ambros4Peter F. Ambros5CCRI, Children's Cancer Research Institute, St. Anna KinderkrebsforschungCCRI, Children's Cancer Research Institute, St. Anna KinderkrebsforschungCCRI, Children's Cancer Research Institute, St. Anna KinderkrebsforschungCCRI, Children's Cancer Research Institute, St. Anna KinderkrebsforschungDept. of Pediatrics, Medical University of Vienna, Vienna, AustriaCCRI, Children's Cancer Research Institute, St. Anna KinderkrebsforschungNeuroblastoma serves as a paradigm for applying tumor genomic data for determining patient prognosis and thus for treatment allocation. MYCN status, i.e. amplified vs. non-amplified, was one of the very first biomarkers in oncology to discriminate aggressive from less aggressive or even favorable clinical courses of neuroblastoma. However, MYCN amplification is by far not the only genetic change associated with unfavorable clinical courses: so called segmental chromosomal aberrations, i.e. gains or losses of chromosomal fragments, can also indicate tumor aggressiveness. The clinical use of these genomic aberrations has, however, been hampered for many years by methodical and interpretational problems. Only after reaching worldwide consensus on markers, methodology, and data interpretation, information on SCAs has recently been implemented in clinical studies. Now, a number of collaborative studies within COG, GPOH and SIOPEN use genomic information to stratify therapy for patients with localized and metastatic disease. Recently, new types of DNA based aberrations influencing the clinical behavior of neuroblastomas have been described. Deletions or mutations of genes like ATRX and a phenomenon referred to as chromothripsis are all assumed to correlate with an unfavorable clinical behavior. However, these genomic aberrations need to be scrutinized in larger studies applying the most appropriate techniques. Single nucleotide polymorphism (SNP) arrays have proven successful in deciphering genomic aberrations of cancer cells; these techniques, however, are usually not applied in the daily routine. Here, we present an ultra-high density (UHD) SNParray technique which is, because of its high specificity and sensitivity and the combined copy number and allele information, highly appropriate for the genomic diagnosis of neuroblastoma and other malignancies.http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00202/fullNeuroblastomaAmplificationgenetic risk factorsGenomicchromothripsisprecision medicine |
| spellingShingle | Inge M. Ambros Clemens eBrunner Reza eAbbasi Christian eFrech Peter F. Ambros Peter F. Ambros Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics Frontiers in Oncology Neuroblastoma Amplification genetic risk factors Genomic chromothripsis precision medicine |
| title | Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics |
| title_full | Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics |
| title_fullStr | Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics |
| title_full_unstemmed | Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics |
| title_short | Ultra-high Density SNParray in Neuroblastoma Molecular Diagnostics |
| title_sort | ultra high density snparray in neuroblastoma molecular diagnostics |
| topic | Neuroblastoma Amplification genetic risk factors Genomic chromothripsis precision medicine |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00202/full |
| work_keys_str_mv | AT ingemambros ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics AT clemensebrunner ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics AT rezaeabbasi ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics AT christianefrech ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics AT peterfambros ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics AT peterfambros ultrahighdensitysnparrayinneuroblastomamoleculardiagnostics |